Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss

June 23, 2026 updated by: Hatice Yemenoğlu, Recep Tayyip Erdogan University Training and Research Hospital

Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss and Oxidative Stress

Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.

A total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Recep Tayyip Erdoğan University Faculty of Dentistry

Description

Inclusion Criteria:

  • Being between 18 and 65 years of age
  • Being systemically healthy or diagnosed with hyperuricemia
  • Having at least 20 natural teeth
  • Being periodontally healthy or diagnosed with periodontitis

Exclusion Criteria:

  • Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.
  • Smoking
  • Pregnancy or lactation
  • Having received periodontal treatment within the last 3-6 months
  • Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs
  • Presence of systemic diseases that may affect purine metabolism

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1: Individuals with periodontitis and hyperuricemia
Other: Collection of gingival crevicular fluid (GCF) and serum samples
Serum and GCF samples will be collected from participants in the first session
Other: Measurement of periodontal clinical parameters
Periodontal clinical parameters will be measured from participants initially
Group 2: Periodontally healthy individuals with hyperuricemia
Other: Collection of gingival crevicular fluid (GCF) and serum samples
Serum and GCF samples will be collected from participants in the first session
Other: Measurement of periodontal clinical parameters
Periodontal clinical parameters will be measured from participants initially
Group 3: Individuals with periodontitis but without hyperuricemia
Other: Collection of gingival crevicular fluid (GCF) and serum samples
Serum and GCF samples will be collected from participants in the first session
Other: Measurement of periodontal clinical parameters
Periodontal clinical parameters will be measured from participants initially
Group 4: Periodontally healthy individuals without hyperuricemia
Other: Collection of gingival crevicular fluid (GCF) and serum samples
Serum and GCF samples will be collected from participants in the first session
Other: Measurement of periodontal clinical parameters
Periodontal clinical parameters will be measured from participants initially

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Periodontal pocket depth
Time Frame: at baseline
The distance between the gingival margin and the base of the pocket will be measured in millimeters.
at baseline
clinical attachment loss
Time Frame: at baseline
The distance between the enamel-cementum junction and the base of the pocket will be measured in millimeters.
at baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Level of interleukin-1 beta
Time Frame: at baseline
Interleukin-1 beta levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
at baseline
Level of interleukin-10
Time Frame: at baseline
Interleukin-10 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
at baseline
Level of interleukin-18
Time Frame: at baseline
Interleukin-18 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Recep Tayyip Erdogan University Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 10, 2026

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

June 8, 2026

First Submitted That Met QC Criteria

June 18, 2026

First Posted (Actual)

June 24, 2026

Study Record Updates

Last Update Posted (Actual)

June 26, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025/302

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontal Diseases

Clinical Trials on Collection of gingival crevicular fluid (GCF) and serum samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe